# Study Assessing the Effect of 3-week Treatment With One of Three Oral Doses of Quinagolide

> **NCT00329693** · PHASE2 · COMPLETED · sponsor: **Ferring Pharmaceuticals** · enrollment: 182 (actual)

## Conditions studied

- Ovarian Hyperstimulation Syndrome

## Interventions

- **DRUG:** Norprolac
- **DRUG:** Norprolac
- **DRUG:** Norprolac
- **DRUG:** Norprolac

## Key facts

- **NCT ID:** NCT00329693
- **Lead sponsor:** Ferring Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-06
- **Primary completion:** 2007-08
- **Final completion:** 2008-05
- **Target enrollment:** 182 (ACTUAL)
- **Last updated:** 2011-05-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00329693

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00329693, "Study Assessing the Effect of 3-week Treatment With One of Three Oral Doses of Quinagolide". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00329693. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*